ÂÜÀòÂÒÂ×

Tony Piscopio is the co-founder, Chief Executive Officer, and President of OnKure, Inc. He is a serial entrepreneur with executive leadership experience spanning more than two decades in the life sciences industry. Most recently, Dr. Piscopio served as Board Chairman and Chief Executive Officer at Chemizon, Inc., a global drug discovery organization where he was responsible for managing operations in the U.S., Seoul, Korea, and Beijing, China, and oversaw the acquisition of the company to Taihan Electric Wire Co. after two years of operation. Previously, Dr. Piscopio co-founded Array BioPharma (ARRY; NASDAQ), where he served as Vice President of Chemistry and was responsible for strategy, new product development, GMP manufacturing, process research, parallel synthesis on an industrial scale, and oncology drug discovery. Prior to Array, Dr. Piscopio was a founding member of Amgen’s small molecule drug discovery division in Boulder, Colorado, and served as a research scientist at Pfizer. He was an NIH Postdoctoral Fellow at The Scripps Research Institute and received a Ph.D. at the University of Wisconsin-Madison.